<DOC>
	<DOCNO>NCT02696148</DOCNO>
	<brief_summary>This trial conduct United States America . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) liraglutide obese child age 7 11 year</brief_summary>
	<brief_title>A Trial Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics Liraglutide Obese Children Aged 7 11 Years</brief_title>
	<detailed_description />
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female subject age 711 year ( inclusive ) time sign informed consent Tanner stage 1 ( include subject premature adrenarche ) time sign informed consent BMI ( body mass index ) correspond equal 30 kg/m^2 adult international cutoff point ( Cole et al 2000 ) 1 BMI equal 45 kg/m^2 well BMI equal 95th percentile age gender Subjects secondary cause childhood obesity ( i.e. , hypothalamic , genetic endocrine cause ) Subjects confirm bulimia nervosa disorder Diagnosis type 1 diabetes mellitus type 2 diabetes mellitus define glycosylated haemoglobin ( HbA1C ) Above equal 6.5 % History pancreatitis ( acute chronic ) Presence severe comorbidities judge investigator Family personal history multiple endocrine neoplasia type 2 ( MEN2 ) medullary thyroid carcinoma ( MTC ) History major depressive disorder within 2 year randomisation</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>